Dantrolene Sodium

CHEMBL928 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
336.2 g/mol
LogP
Phase
4

The sodium salt form of dantrolene used as an injectable for malignant hyperthermia emergencies and orally for chronic spasticity from conditions such as multiple sclerosis or cerebral palsy. It reduces muscle tone by directly blocking calcium-mediated contraction.

Masse moléculaire

336,2300 g/mol

TPSA

127,00 Ų

Aires thérapeutiques

Mécanisme d'action

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)[N-]1.[Na+]

InChI

InChI=1S/C14H10N4O5.Na/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;/h1-7H,8H2,(H,16,19,20);/q;+1/p-1/b15-7+;

Molecular Formula

C14H9N4NaO5

HBD / HBA

- / 6

Liaisons Rotatives

3

Atomes Lourds

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

The sodium salt form of dantrolene used as an injectable for malignant hyperthermia emergencies and orally for chronic spasticity from conditions such as multiple sclerosis or cerebral palsy. It reduces muscle tone by directly blocking calcium-mediated contraction.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Dantrolene Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL928. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6604100. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.